News & Updates
Filter by Specialty:
COVID-19 does mess with the brain even years after infection
A long-term study showed that individuals who have recovered from COVID-19 continued to experience cognitive, psychiatric, and neurological issues, as well as brain functional alteration, even 2 years after being infected.
COVID-19 does mess with the brain even years after infection
06 Jun 2024
FMT eases anxiety, sleep disturbance in postacute COVID-19 syndrome patients
Patients with postacute COVID-19 syndrome (PACS) may benefit from faecal microbiota transplantation (FMT) treatment, which helps reduce anxiety and improve sleep quality, suggests a study.
FMT eases anxiety, sleep disturbance in postacute COVID-19 syndrome patients
05 Jun 2024
Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19
A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.
Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19
05 Jun 2024
SABA overused, increases all-cause mortality among HK asthma patients
Overuse of short-acting β2 agonists (SABA) is prevalent among patients with asthma in Hong Kong and associated with an increased risk of all-cause mortality and hospital admissions, according to a local retrospective cohort study, which was part of the global SABINA (SABA Use in Asthma) research programme.
SABA overused, increases all-cause mortality among HK asthma patients
01 Jun 2024
Arginine depletion plus chemo ups survival in rare lung cancer
In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.
